TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06625177: A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo

Sponsor: Teva Branded Pharmaceutical Products R&D LLC · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 66 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$859,656

Rescue Site Savings

+$561,408

Unlock Full NCT06625177 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06625177 Rescue Dossier →